Accessibility Menu
PharmX Technologies logo

PharmX Technologies(ASX) COO

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1992)-99%
5 Year+35%
1 Year-7%
1 Month-15%
N/A
PharmX Technologies last closing stock price
MetricPriceDate
Last closeAUD 0.102026-08-14
PharmX Technologies stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-2%AUD 0.102026-08-07
1 month-14.78%AUD 0.122026-07-15
3 month-10.91%AUD 0.112026-05-14
Year to date-38.75%AUD 0.162025-12-31
1 year-6.67%AUD 0.112025-08-14
3 year+136.14%AUD 0.042023-08-15
5 year+34.55%AUD 0.072021-08-13
Since inception-99.12%AUD 11.191992-01-02

PharmX Technologies Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$17.26M

Net Income (TTM)

A$1.18M

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

Aug 23, 2023

COO News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About PharmX Technologies

Corum Group Limited is an Australian technology and software development firm focused on the Health Service sector. The company specializes in creating business software solutions tailored for the pharmacy industry, including electronic ordering portals and point-of-sale systems.

Products and Services
  • Electronic ordering portal for pharmacies
  • Point-of-sale (POS) systems
  • Software for pharmaceutical dispensing and retail management
Growth Outlook
  • Recent quarterly revenue reached AUD 10.42 million, a significant increase
  • Gross profit margin improved to 84.32% in the latest quarter
  • Strong demand for pharmacy software solutions supports future growth
Financial Highlights
  • Trailing twelve months (TTM) revenue of AUD 27.4 million
  • Net income margin of -17.46% indicates potential for recovery
  • Current ratio of 1.84 suggests strong liquidity position
Corum Group Limited operates in a niche market with a focus on healthcare technology, specifically for pharmacies. The company's recent financial performance shows promising growth, particularly in revenue and gross profit margins. The increase in quarterly revenue to AUD 10.42 million reflects a robust demand for its software solutions, which are essential for modern pharmacy operations. The gross profit margin of 84.32% indicates effective cost management and a strong value proposition for customers. Despite a negative net income margin, the company is positioned to leverage its current assets effectively, as evidenced by a current ratio of 1.84, which suggests a solid liquidity position. Overall, Corum Group Limited presents an intriguing opportunity for investors interested in the healthcare technology sector, particularly as the demand for pharmacy-related software solutions continues to grow.
AI Generated • Aug 9, 2026

Industry

Software

Sector

Information Technology

CEO

Tom Culver

Website

pharmx.com.au

Headquarters

Sydney, NSW 2000, AU

COO Financials

Key Financial Metrics (TTM)

Gross Margin

79.89%

Operating Margin

-11.05%

Net Income Margin

-17.46%

Return on Equity

-4.63%

Return on Capital

-2.99%

Return on Assets

-2.88%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

A$14.72M

Operating Income

A$829.00K

EBITDA

A$3.98M

Operating Cash Flow

A$0.00

Capital Expenditure

-A$7.37M

Free Cash Flow

-A$7.37M

Cash & ST Invst.

A$12.81M

Total Debt

A$32.00K

PharmX Technologies Performance Analysis

PharmX Technologies annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-06-30AUD 5,356,000N/A
20232023-06-30AUD 6,018,00012.4%
20242024-06-30AUD 6,487,0007.8%
20252025-06-30AUD 7,320,00012.8%
PharmX Technologies sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22020-12-30N/A
Q42021-06-30357.3%
Q42022-06-30N/A
Q42023-06-30N/A
PharmX Technologies annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-06-30AUD 0.00N/A
20232023-06-30AUD -0.00N/A
20242024-06-30AUD -0.0027.8%
20252025-06-30AUD -0.00-82.6%
PharmX Technologies sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22020-12-30N/A
Q42021-06-30800.0%
Q42022-06-30N/A
Q42023-06-30N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2020YOY CHG

Revenue

A$10.42M

+311.2%

Gross Profit

A$8.79M

+290.9%

Gross Margin

84.32%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

109

N/A

Net Income

A$1.05M

+199.6%

EBITDA

A$2.99M

+435.2%

Quarterly Fundamentals

Name
Q4 2020YOY CHG

Total Cash

A$12.81M

+448.9%

Total Debt

A$32.00K

N/A

Accounts Receivable

A$946.00K

-59.0%

Inventory

A$0.00

-100.0%

Long Term Debt

A$0.00

N/A

Short Term Debt

A$32.00K

N/A

Return on Assets

-2.88%

N/A

Return on Invested Capital

-2.74%

N/A

Free Cash Flow

-A$3.27M

-91.6%

Operating Cash Flow

A$0.00

N/A

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
LCT.AXLiving Cell Technologies Limited
A$0.02+7.14%
1ST.AX1st Group Limited
A$0.01+22.22%
CPH.AXCreso Pharma Limited
A$0.01+0.00%
MXC.AXMGC Pharmaceuticals Limited
A$0.42+2.44%

Trending Stocks

Symbol / CompanyPricePrice Chg
NUNu Holdings
$15.23+0.09%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.76+0.01%
ONDSOndas
$9.24+0.04%
SPCXSpace Exploration Technologies
$140.00-0.01%

Questions About COO

What is the current price of PharmX Technologies?

PharmX Technologies is trading at N/A per share.

What is the 52-week range for PharmX Technologies?

Over the past 52 weeks, PharmX Technologies has traded between N/A and N/A.

How much debt does PharmX Technologies have?

As of the most recent reporting period, PharmX Technologies reported total debt of A$894.00K.

How much cash does PharmX Technologies have on hand?

PharmX Technologies reported A$4.17M in cash and cash equivalents in its most recent financial results.

What is PharmX Technologies’s dividend yield?

PharmX Technologies does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services